PAR2 agonists for use in the treatment or prevention of influenza virus type A infections

US9125861B2 · kind B2 · utility

Assignees

• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• INSTITUT NATIONAL DE LA RECHERCHE AGRONOMQIUE · FR

Inventors

• Nathalie Vergnolle · Toulouse, FR
• Béatrice Riteau · Beynes, FR

Key dates

• Filing date: May 3, 2010
• Grant date: Sep 8, 2015
• Expiry date: Dec 16, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods and compositions (such as pharmaceutical compositions) for treating influenza virus type A infections in human subjects include PAR2 agonists being administered to the subject. The PAR2 agonists include small organic molecules, antibodies, and aptamers. In addition, the PAR2 agonist may be a PAR2 activating peptide. Exemplary PAR2 activating peptides include SLIGRL (SEQ ID NO: 1) and SLIGKV (SEQ ID NO: 2).